Diligence memo · auto-generated · as of July 3, 2026
Harmony Biosciences II, Inc.
Harmony Biosciences II, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Harmony Biosciences II, Inc. operates in Pharmaceuticals, based in PLYMOUTH MEETING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Harmony Biosciences II, Inc. has raised $345M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $270M on 2017-09-22.
Most recent recorded round closed around 2019-08-09.
Valuation (modeled)modeled
Provath models Harmony Biosciences II, Inc. at approximately $1.8B (range $238M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 6.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Vyripharm Enterprises, Inc., Verona Pharma plc, Cingulate Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.